ArticleVeterinary research communications2026
Development of a recombinant glycoprotein E-based ELISA for detection of antibodies against Bovine alphaherpesvirus 1: a DIVA compliant.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis (IBR/IPV) caused by Bovine alphaherpesvirus-1 belongs to the family Orthoherpesviridae subfamily Alphaherpesvirinae, and genus Varicellovirus. The use of IBR marker vaccines necessitates the development of diagnostic assays targeting glycoprotein E (gE) to differentiate infected animals from vaccinated ones. In the present study, the N-terminal one-third region of the gE gene was cloned and expressed in a prokaryotic expression system. The recombinant gE protein (~ 25 kDa) was confirmed to be immunogenic by western blot analysis using bovine hyperimmune serum. The purified recombinant protein was subsequently utilized for the development of an indirect ELISA. A total of 456 bovine serum samples, comprising 206 gE-positive and 250 gE-negative as determined by the IDEXX IBR gE ELISA, were employed for standardization of the in house rgE ELISA. Statistical analysis identified an optimal cut-off value of 45.92 percent positivity (PP), at which the assay demonstrated a diagnostic sensitivity of 84.9% and specificity of 91.2%. The area under the ROC curve was 0.914 at 95% confidence interval, indicating assay could be used for mass screening.
Indexed as
Identifiers
42839185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.